Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00592436 · ClinicalTrials.gov registry record
Screening Protocol for Children and Adolescents With Attention Deficit Hyperactivity Disorder
A clinical trial, sponsored by Massachusetts General Hospital.
- Terminated
- Registry status
- 663
- Enrollment target
NCT00592436: Clinical Trial study, sponsored by Massachusetts General Hospital.
NCT00592436 is a clinical trial that was terminated before completion, run by Massachusetts General Hospital. The registered enrollment target is 663 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00592436 was terminated before completion, sponsored by Massachusetts General Hospital.
- TERMINATED
- Registry status
- 663 participants
- Enrollment target
Study Summary
The objective of this protocol is to establish a comprehensive screening process to evaluate the eligibility of potential pediatric subjects for appropriate ADHD clinical research studies.
Primary Outcome
This is a prescreening for potential participation in research studies.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 663 participants |
| Start Date | 2003-03 |
| Est. Completion | 2015-05 |
Why NCT00592436 stopped before completion
NCT00592436 is an observational study that tracks outcomes without assigning an intervention. The registered 663 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT00592436 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00592436 about?
NCT00592436 is a clinical study titled "Screening Protocol for Children and Adolescents With Attention Deficit Hyperactivity Disorder". The objective of this protocol is to establish a comprehensive screening process to evaluate the eligibility of potential pediatric subjects for appropriate ADHD clinical research studies.
What is the current status of trial NCT00592436?
This trial is currently terminated. The enrollment target is 663 participants. The study started on 2003-03. Estimated completion is 2015-05.
Who is sponsoring clinical trial NCT00592436?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07164443 · 663 participants · Phase 3
A Study of Pasritamig Versus Placebo in Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
- NCT06607341 · 664 participants · NA
Community Engagement Alliance Against Disparities
- NCT05254743 · 662 participants · Phase 3
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- NCT04064060 · 665 participants · Phase 3
A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia